Real-world adoption of the 2023 European Society of Cardiology guidelines regarding antiplatelet strategies in acute coronary syndromes : Insights from the European READAPT-2 survey
Background The 2023 European Society of Cardiology (ESC) guidelines for acute coronary syndromes (ACS) maintained a Class III recommendation against routine pretreatment with oral P2Y12 inhibitors in non-ST-segment elevation ACS (NSTE-ACS) and downgraded pretreatment in ST-segment elevation myocardial infarction (STEMI) to Class IIb. This study evaluated real-world uptake of these recommendations
